Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2666680 | 0.98 | ALDH1A1 (0.41) | ALDH1A1MEN1MAPTBLMKMT2A | |
| SCHEMBL10236227 | 0.91 | — | — | |
| SCHEMBL2492091 | 0.77 | ALDH1A1 (0.45) | ALDH1A1MEN1MAPTBLMKMT2A | |
| SCHEMBL2491342 | 0.75 | MEN1 (0.44) | ALDH1A1MEN1MAPTBLMKMT2A | |
| SCHEMBL2546676 | 0.74 | ALDH1A1 (0.42) | ALDH1A1MEN1MAPTBLMKMT2A | |
| SCHEMBL18615155 | 0.72 | ALDH1A1 (0.41) | ALDH1A1MEN1MAPTBLMKMT2A | |
| SCHEMBL2651142 | 0.72 | MEN1 (0.41) | ALDH1A1MEN1MAPTBLMKMT2A | |
| SCHEMBL31456615 | 0.72 | MEN1 (0.41) | ALDH1A1MEN1MAPTBLMKMT2A | |
| SCHEMBL6900253 | 0.72 | ALDH1A1 (0.37) | ALDH1A1MEN1MAPTBLMKMT2A | |
| SCHEMBL12050030 | 0.72 | ALDH1A1 (0.37) | ALDH1A1MEN1MAPTBLMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754100-B2 | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-06-17 | — | — | US | disclosed |
| US-20120053171-A1 | Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2012-03-01 | — | — | US | disclosed |
| US-7973033-B2 | Multi-cyclic cinnamide derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-7973033-B2 | Multi-cyclic cinnamide derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20110112138-A1 | MULTI-CYCLIC CINNAMIDE DERIVATIVES | KIMURA TEIJI | 2011-05-12 | — | — | US | disclosed |
| US-20110112138-A1 | MULTI-CYCLIC CINNAMIDE DERIVATIVES | KIMURA TEIJI | 2011-05-12 | — | — | US | disclosed |
| US-7713993-B2 | Multi-cycle cinnamide derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-05-11 | — | — | US | disclosed |
| US-7713993-B2 | Multi-cycle cinnamide derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053171-A1 | Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors | BACE1, APP, PSEN1 | ALDH1A1 3158/4885MEN1 387/4885MAPT 8/4885 |
| US-20110112138-A1 | MULTI-CYCLIC CINNAMIDE DERIVATIVES | BACE1, APP, PSEN1 | ALDH1A1 1045/4885MEN1 771/4885MAPT 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.